VentriPoint Diagnostics Ltd (TSE:VPT)
:VPT
Want to see TSE:VPT full AI Analyst Report?
VPT Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume32.00K
Average Volume (3M)106.78K
Market Cap
C$27.21M
Enterprise ValueC$30.70M
Total Cash (Recent Filing)C$55.39K
Total Debt (Recent Filing)C$2.60M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding187,659,200
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~245% year-over-year revenue surge in 2025 indicates robust demand and accelerating adoption of the company’s products. This durable top-line momentum provides a foundation to build scale and unit economics over the next 2–6 months if managed with disciplined cost control and continued market expansion.
Improving Gross MarginGross margin expanding to ~66% signals improving unit economics and pricing or cost improvements at the product level. Sustained higher gross margins create a structural buffer to absorb SG&A, making a durable path toward operating profitability more plausible if operating expenses growth is contained.
Asset-light / Small TeamA very small headcount (10 employees) suggests an asset-light operating model with lower fixed payroll overhead. This structural characteristic can enable revenue scaling without proportional SG&A increases, helping extend runway and potentially improve operating leverage if revenue growth persists.
Bears Say
Weak Balance SheetDeeply negative equity and rising debt materially weaken financial flexibility and increase refinancing and dilution risk. With limited asset backing (~$0.47M assets), the company faces constrained capacity to fund operations or invest organically without external capital, a persistent structural vulnerability.
Persistent Cash BurnConsistent negative operating cash flow, including -$1.6M in 2025, shows losses convert into real cash outflows. This ongoing cash burn necessitates external financing to sustain operations and elevates the risk of dilution or restricted growth unless cash generation improves or funding is secured.
Lack Of Operating LeverageDespite rapid revenue growth, extremely negative net margins and large operating losses indicate the company has not yet achieved operating leverage. Without meaningful margin expansion or cost containment, scaling revenue will likely continue to produce cash losses, impairing durable profitability prospects.
VPT FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is C$27.21M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Jun 02, 2026 which is in 13 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
Currently, no data Available
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 187,659,200 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model of the heart chamber using echocardiograms and magnetic resonance imaging images; and obtain reproducible, accurate volumetric measurement, and ejection fraction. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and Covid-19 related heart issues. The company was incorporated in 2004 and is based in Toronto, Canada.
Technical Analysis
Imagin Medical
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
―
Options Prices
Currently, No data available
---